Frontiers in Microbiology (Sep 2024)
Causality investigation among gut microbiota, immune cells, and prostate diseases: a Mendelian randomization study
- Shao-Yu Yue,
- Shao-Yu Yue,
- Shao-Yu Yue,
- Wei-Yi Li,
- Wei-Yi Li,
- Wei-Yi Li,
- Shun Xu,
- Shun Xu,
- Shun Xu,
- Xiao-Xin Bai,
- Wen-Long Xu,
- Wen-Long Xu,
- Wen-Long Xu,
- Xu Wang,
- Xu Wang,
- Xu Wang,
- He-Kang Ding,
- He-Kang Ding,
- He-Kang Ding,
- Jia Chen,
- Jia Chen,
- Jia Chen,
- He-Xi Du,
- He-Xi Du,
- He-Xi Du,
- Ling-Fan Xu,
- Ling-Fan Xu,
- Ling-Fan Xu,
- Di Niu,
- Di Niu,
- Di Niu,
- Chao-Zhao Liang,
- Chao-Zhao Liang,
- Chao-Zhao Liang
Affiliations
- Shao-Yu Yue
- Department of Urology, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China
- Shao-Yu Yue
- Institute of Urology, Anhui Medical University, Hefei, China
- Shao-Yu Yue
- Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Anhui Medical University, Hefei, China
- Wei-Yi Li
- Department of Urology, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China
- Wei-Yi Li
- Institute of Urology, Anhui Medical University, Hefei, China
- Wei-Yi Li
- Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Anhui Medical University, Hefei, China
- Shun Xu
- Department of Urology, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China
- Shun Xu
- Institute of Urology, Anhui Medical University, Hefei, China
- Shun Xu
- Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Anhui Medical University, Hefei, China
- Xiao-Xin Bai
- Department of Infectious Disease, The Second People’s Hospital of Fuyang City, Fuyang, China
- Wen-Long Xu
- Department of Urology, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China
- Wen-Long Xu
- Institute of Urology, Anhui Medical University, Hefei, China
- Wen-Long Xu
- Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Anhui Medical University, Hefei, China
- Xu Wang
- Department of Urology, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China
- Xu Wang
- Institute of Urology, Anhui Medical University, Hefei, China
- Xu Wang
- Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Anhui Medical University, Hefei, China
- He-Kang Ding
- Department of Urology, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China
- He-Kang Ding
- Institute of Urology, Anhui Medical University, Hefei, China
- He-Kang Ding
- Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Anhui Medical University, Hefei, China
- Jia Chen
- Department of Urology, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China
- Jia Chen
- Institute of Urology, Anhui Medical University, Hefei, China
- Jia Chen
- Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Anhui Medical University, Hefei, China
- He-Xi Du
- Department of Urology, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China
- He-Xi Du
- Institute of Urology, Anhui Medical University, Hefei, China
- He-Xi Du
- Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Anhui Medical University, Hefei, China
- Ling-Fan Xu
- Department of Urology, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China
- Ling-Fan Xu
- Institute of Urology, Anhui Medical University, Hefei, China
- Ling-Fan Xu
- Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Anhui Medical University, Hefei, China
- Di Niu
- Department of Urology, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China
- Di Niu
- Institute of Urology, Anhui Medical University, Hefei, China
- Di Niu
- Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Anhui Medical University, Hefei, China
- Chao-Zhao Liang
- Department of Urology, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China
- Chao-Zhao Liang
- Institute of Urology, Anhui Medical University, Hefei, China
- Chao-Zhao Liang
- Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Anhui Medical University, Hefei, China
- DOI
- https://doi.org/10.3389/fmicb.2024.1445304
- Journal volume & issue
-
Vol. 15
Abstract
BackgroundThe gut microbiota has been demonstrated to have a significant role in the pathogenesis and progression of a variety of diseases, including prostate cancer, prostatitis, and benign prostatic hyperplasia. Potential links between prostate diseases, immune cells and the gut microbiota have not been adequately investigated.MethodsMR studies were conducted to estimate the effects of instrumental variables obtained from genome-wide association studies (GWASs) of 196 gut microbial taxa and 731 immune cells on the risk of prostate diseases. The primary method for analysing causal relationships was inverse variance-weighted (IVW) analysis, and the MR results were validated through various sensitivity analyses.ResultsMR analysis revealed that 28 gut microbiome taxa and 75 immune cell types were significantly associated with prostate diseases. Furthermore, reverse MR analysis did not support a causal relationship between prostate diseases and the intestinal microbiota or immune cells. Finally, the results of the mediation analysis indicated that Secreting Treg % CD4 Treg, Activated & resting Treg % CD4 Treg, and Mo MDSC AC inhibited the role of the class Mollicutes in reducing the risk of PCa. In prostatitis, CD8+ T cells on EM CD8br hinder the increased risk associated with the genus Eubacterium nodatum group. Interestingly, in BPH, CD28- CD25++CD8br AC and CD16-CD56 on HLA DR+ NK promoted the role of the genus Dorea in reducing the risk of BPH.ConclusionThis study highlights the complex relationships among the gut microbiota, immune cells and prostate diseases. The involvement of the gut microbiota in regulating immune cells to impact prostate diseases could provide novel methods and concepts for its therapy and management.
Keywords
- prostate diseases
- immune cells
- mediating effect
- Mendelian randomization analysis
- prostate cancer
- prostatitis
